These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37881139)

  • 21. Successful Bacteriophage-Antibiotic Combination Therapy against Multidrug-Resistant
    Racenis K; Lacis J; Rezevska D; Mukane L; Vilde A; Putnins I; Djebara S; Merabishvili M; Pirnay JP; Kalnina M; Petersons A; Stradins P; Maurins S; Kroica J
    Viruses; 2023 May; 15(5):. PubMed ID: 37243293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future.
    Łobocka M; Dąbrowska K; Górski A
    BioDrugs; 2021 May; 35(3):255-280. PubMed ID: 33881767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative analysis of effectiveness for phage cocktail development against multiple Salmonella serovars and its biofilm control activity.
    Ribeiro JM; Pereira GN; Durli Junior I; Teixeira GM; Bertozzi MM; Verri WA; Kobayashi RKT; Nakazato G
    Sci Rep; 2023 Aug; 13(1):13054. PubMed ID: 37567926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phage therapy as a glimmer of hope in the fight against the recurrence or emergence of surgical site bacterial infections.
    Moghadam MT; Mojtahedi A; Salamy S; Shahbazi R; Satarzadeh N; Delavar M; Ashoobi MT
    Infection; 2024 Apr; 52(2):385-402. PubMed ID: 38308075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ameliorating the antimicrobial resistance crisis: phage therapy.
    Saha D; Mukherjee R
    IUBMB Life; 2019 Jul; 71(7):781-790. PubMed ID: 30674079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic Antibacterial Effect of Phage pB3074 in Combination with Antibiotics Targeting Cell Wall against Multidrug-Resistant Acinetobacter baumannii
    Luo J; Xie L; Yang M; Liu M; Li Q; Wang P; Fan J; Jin J; Luo C
    Microbiol Spectr; 2023 Aug; 11(4):e0034123. PubMed ID: 37260382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How Good are Bacteriophages as an Alternative Therapy to Mitigate Biofilms of Nosocomial Infections.
    Singh A; Padmesh S; Dwivedi M; Kostova I
    Infect Drug Resist; 2022; 15():503-532. PubMed ID: 35210792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating bacterial infections with bacteriophages in the 21st century.
    Opperman CJ; Wojno JM; Brink AJ
    S Afr J Infect Dis; 2022; 37(1):346. PubMed ID: 35399556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of Novel
    Mulani MS; Kumkar SN; Pardesi KR
    Microbiol Spectr; 2022 Dec; 10(6):e0199422. PubMed ID: 36374021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bacteriophage Endolysin: A Powerful Weapon to Control Bacterial Biofilms.
    Liu B; Guo Q; Li Z; Guo X; Liu X
    Protein J; 2023 Oct; 42(5):463-476. PubMed ID: 37490161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical phage microbiology: a narrative summary.
    Suh GA; Patel R
    Clin Microbiol Infect; 2023 Jun; 29(6):710-713. PubMed ID: 36805835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of phages for the removal of infectious biofilms.
    Azeredo J; Sutherland IW
    Curr Pharm Biotechnol; 2008 Aug; 9(4):261-6. PubMed ID: 18691087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phage therapy--constraints and possibilities.
    Nilsson AS
    Ups J Med Sci; 2014 May; 119(2):192-8. PubMed ID: 24678769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacteriophage therapy: an overview and the position of Italian Society of Infectious and Tropical Diseases.
    Cesta N; Di Luca M; Corbellino M; Tavio M; Galli M; Andreoni M
    Infez Med; 2020 Sep; 28(3):322-331. PubMed ID: 32920567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolation and Characterization of Novel Lytic Phages Infecting Multidrug-Resistant Escherichia coli.
    Vera-Mansilla J; Sánchez P; Silva-Valenzuela CA; Molina-Quiroz RC
    Microbiol Spectr; 2022 Feb; 10(1):e0167821. PubMed ID: 35171030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phage-based therapy against biofilm producers in gram-negative ESKAPE pathogens.
    Ragupathi NKD; Muthuirulandi Sethuvel DP; Gopikrishnan M; Dwarakanathan HT; Murugan D; Biswas I; Bakthavachalam YD; Murugesan M; George Priya Doss C; Monk PN; Karunakaran E; Veeraraghavan B
    Microb Pathog; 2023 May; 178():106064. PubMed ID: 36898591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aminoglycosides Antagonize Bacteriophage Proliferation, Attenuating Phage Suppression of Bacterial Growth, Biofilm Formation, and Antibiotic Resistance.
    Zuo P; Yu P; Alvarez PJJ
    Appl Environ Microbiol; 2021 Jul; 87(15):e0046821. PubMed ID: 34020940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacteriophage-Host Interactions and the Therapeutic Potential of Bacteriophages.
    Dicks LMT; Vermeulen W
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
    Luong T; Salabarria AC; Roach DR
    Clin Ther; 2020 Sep; 42(9):1659-1680. PubMed ID: 32883528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engineered phage with cell-penetrating peptides for intracellular bacterial infections.
    Zhao M; Tan X; Liu Z-q; Dou L; Liu D; Pan Y-j; Ma Y-f; Yu J-l
    mSystems; 2023 Oct; 8(5):e0064623. PubMed ID: 37594262
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.